Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs were updated May 1, 2025:
Effective June 1, 2025:
- Crenessity
- Enjaymo
- Galafold
- HCPA Biologic
- Healthcare Administered MS
- IL-1 Inhibitors
- IL-5 Inhibitors
- IL-13 Antagonist
- Lupus
- Otezla
- Phosphate Binders
- SA Oncology
- Spevigo SC
- Substrate Reduction Therapy
- Tryngolza
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions please contact your BCBSKS provider representative.